down-the-middl updat bullish commentari sustain
wednesday morn octob abbott post anoth consist impress
quarterli result came almost directli line compani guidanc know
say thing last sever quarter abbott continu
post consist growth peer organ sale earn basi
also maintain bullish around sustain growth compani current
portfolio product point look remaind year
biggest question still relat compani massiv
grow cash balanc current growth opportun fulli fund nice
problem abbott
quarter report revenu billion roughli line
street estim though impact increment basi point fx headwind sinc
juli call compar oper basi revenu growth constant currenc
touch higher midpoint guidanc quarter strength came
sever segment medic devic continu star constant
current quarter driven diabet led freestyl libr sale nearli
million quarter structur heart led mitraclip grew fxn
addit stori diagnost chang growth led
global roll-out alin importantli manag believ momentum continu
enter next year state see chang momentum chang progress
chang growth rate ask next year given team track record
last eight quarter organ fxn growth averag give us confid
revenu growth estim
earn perspect ep grew report came
model low end guidanc enter fourth
quarter oper margin call pick basi point sequenti basi
look next year see issu earn per share estim
growth continu strong invest product line
expect drive consist sale growth peer throughout come year
return equiti ttm
abbott highli diversifi provid medic devic nutrit pharmaceut product
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
lastli secret abbott cash balanc continu grow net leverag continu trickl time
phenomenon rais question capit deploy realli direct answer point manag continu
state prioriti includ new product manufactur capac fulli fund pay debt allow
refinanc rais dividend though seem unlik move needl potenti buy back share
compani author billion buy-back earlier week seem ad flexibl anyth
 point seem focus tuck-in type acquisit anyth els larger-scal target
high price tag make sens said high-class problem expect
question around exactli team plan cash sit balanc sheet seem
prudent thing sustain period time
follow today updat continu believ end-market demand remain robust across segment margin
expans play pipelin new product launch continu gain traction back substanti
invest cash flow creat accret opportun believ support current multipl time
forward ep lower account fx impact room upsid result number lever compani
avail result reiter outperform rate
diabet diabet one highlight quarter driven continu strength adopt freestyl
libr fgm system libr highlight includ global sale million year-over-year intern
nearli time growth unit state expand global reimburs coverag especi canada on-going
partnership creat interoper diabet care solut power freestyl libr read manag note libr
million patient user base continu compris type patient libr uniqu valu
proposit drive adopt among type patient expand market among type patient wrote
diabet revolut note link continu believ type market remain key growth driver cgm
technolog next five year believ libr well suit patient
overal perform quarter continu deliv upsid expect continu momentum libr
support increas sensor manufactur capac subsequ greater abil drive libr adopt
advertis market awar
libr despit longer-than-anticip regulatori timelin manag reiter confid gain fda
approv libr icgm design stop short provid expect approv
time note manag believ back forth fda outsid normal product approv
give confid eventu approv libr believ approv launch libr
critic develop abbott interoper diabet care solut given need bluetooth connect
pumps/pen expect manag keenli focus work fda ensur time approv
next-gen sensor approv time remain unclear believ libr plenti momentum sustain
growth near term note libr like need closed-loop pump smart insulin
pen integr abbott leverag current-gener libr sensor partnership like livongo omada
expand type market
tandem partnership octob morn abbott third-quart earn call compani announc
partnership develop integr diabet solut would combin tandem insulin
pump abbott freestyl libr sensor given lack detail provid manag somewhat
ambigu word partnership announc believ effort integr libr slim
ecosystem still earli stage product approv launch could take long month
expect integr solut abbott tandem announc
partnership reliant approv libr sinc next-gen system includ bluetooth technolog
allow commun devic real-tim alert believ abbott addit partnership
announc pump side look better compet type space believ libr like need
support clinic data perhap run closed-loop system make meaning headway market
remain focus regulatori updat libr expect meaning progress integr
partnership said abbott hope earli talk partner help expedit libr integr process
approv unit state surpris abbott continu focu libre-en
integr solut continu believ diabet care move toward interoper environ focus
enabl improv glycem controlsometh wrote extens diabet revolut target
improv glycem control sum encourag on-going convers multipl partner
expect play key role long-term growth freestyl libr
suppli chain expans fuel growth abbott open next tranch libr sensor manufactur capac
third quarter manag believ sensor suppli fulli unconstrain allow sale team get
aggress initi like sensor sampl dtc advertis expect abbott increas sales-
and-market educ expens drive demand exist new market libr nice-
to-hav product launch believ capac increas come could bigger impact result
move
mitraclip/structur heart third-quart structur heart sale grew organ slightli ahead
estim strength quarter attribut continu momentum mitraclip sale global
unit state led exist account bolster earli benefit expand indic treat secondari mitral
regurgit mr overal remain posit durabl mitraclip sale abbott make headway larg
undertr mr opportun low-single-digit penetr market patient expect growth
support launch abbott next-gener mitraclip system abbott focu grow instal base
center overwhelmingli posit grow clinic back see structur heart updat tct
new econom clinic data keep product pump clinic detail taken togeth believ
mitraclip deliv sever year strong momentum
secondari mr reimburs recal abbott file reimburs approv first-quart call
guid reimburs approv earli slight delay origin guidanc late
believ overwhelmingli posit result coapt trial support posit reimburs decis
model meaning sale acceler get detail reimburs
approv manag note expect approv come decemb januari expect
coverag critic sustain mitraclip strong growth profil believ reimburs could even
serv posit inflect point potenti acceler mitraclip sale
neuromodul organ fxn neuromodul one weaker segment within medic devic
sale constant currenc quarter driven declin unit state though
hope turnaround last sever quarter combin ramp salesforc tough market limit
new product launch constrain sale dynam eas come quarter manag mention
stabil salesforc number progress monthli kpi/product indic look
manag show execut recoveri futur quarter
compani receiv fda approv proclaim xr recharge-fre devic earlier octob expect three
product next six nine month includ addit mri compat easier-to-us programm rf
gener individu smaller scale collect expect arm rep competit offer
proclaim xr week launch manag express earli indic demand trial posit
term overal market commentari abbott express expect market growth quarter rel flat though
believ sequenti improv someth watch player report result segment
remain near-term work-in-process may improv modestli come quarter
diagnost organ fxn growth segment follow similar trend saw second
quarter laboratori largest sub-seg lead way organ fxn growth molecular
revenu disappoint declin quarter due declin oncolog busi well hiv hcv
test volum state last quarter overli concern small dollar compar whole
main area growth organ expect stabil head throughout
focu remain compani abil continu grow lab roll-out alin system still
earli inning well abil stabil turn around aler rapid diagnost new product
introduct refresh well continu growth infecti diseas test id platform cardio-
metabol test believ stabil could begin turn growth ngo purchas issu subdu
underli growth diagnost exclud issu closer quarter
relat alin roll-out continu biggest driver revenu growth lab segment
grew unit state fxn intern primarili led on-going uptak product line
immunoassay clinic chemistri platform system put field fulli revenu
gener lab valid complet manag remain extrem bullish model alin note
remain earli inning roll hematolog molecular diagnost offer product famili
manag confirm prior commentari molecular offer expect approv unit state late
mean segment growth like come addit continu see custom retent nearli
system renew gain share win-rat account abbott activ target
entrench competitor strong start roll-out sever year instal base replac capac
invest menu expans believ manag prior commentari alin driver growth
next five seven year hold steadi
china commentari manag provid broad-level comment busi china remain confid
growth continu within geographi pediatr nutrit busi continu see challeng within china
mostli due competit environ abbott discuss challeng separ kind broad trade
econom issu compani sever new product plan pursu addit under-index area within
china tap allow reinvigor growth within pediatr nutrit busi overal abbott remain watch
trade-rel friction china seen slow product demand impact product approv time
across busi outsid challeng pediatr nutrit
posit abbott cash balanc continu grow rais question around manag
deploy asset manag reiter feel comfort capit posit strateg flexibl debt/ebitda
near time compar time end time follow close st jude acquisit
earli abbott also rais dividend last decemb success built strong manufactur capac
new product believ manag go forward may like look aggress tact share repurchas
yesterday announc billion share repurchas author continu increment debt paydown still
open acquisit like target list manag indic near-term plan patient
guidanc manag re-affirmed sale guidanc rang organ constant-curr
growth state would upper end initi guidanc rang addit adjust earn
per share year expect rang reflect growth midpoint
tighten prior rang
fourth quarter team expect sale growth roughli organ fxn basi fx headwind
busi line manag expect high-single-digit growth establish pharmaceut low- midsingle-digit
growth nutrit mid- high-single-digit growth diagnost growth similar seen third
quarter medic devic support double-digit growth sever busi segment view guidanc
achiev beatabl potenti upsid driver stem new product introduct indic expans
name mitraclip libr alin platform
impli adjust earn per share fourth quarter expect rang reflect growth
midpoint
updat model follow quarterli result manag guidanc
sale maintain sale estim billion reflect organ fxn growth report
growth
earn increas earn per share estim reflect annual growth
sale slightli decreas sale estim billion reflect organ fxn growth
new estim larg unchang previou estim
earn increas earn per share estim account third quarter
beat compani recent approv billion share buy-back assum million repurchas per
quarter impli year-over-year growth
